Investing

5 New Red-Hot Stocks Trading Under $10 With Gigantic Upside Potential

Ranger Energy Services

This small-cap oilfield service play also has big upside potential. Ranger Energy Services Inc. (NYSE: RNGR) engages in the provision of service rigs and associated services. It operates through three segments: The High Specification Rig segment provides service rigs and complementary equipment and services.

The Completion and Other Services segment consists of wireline and snubbing lines of business. The Processing Solutions segment is involved in rental, installation, commissioning, start-up, operation and maintenance of mechanical refrigeration units, natural gas liquid (NGL) stabilizer units, NGL storage units and related equipment.

Wells Fargo’s Buy rating comes with an $11 price objective, not far off the consensus target of $10.50. The shares ended the week trading at $8.39.

Recro Pharma

This stock was pounded recently and offers a great entry point. Recro Pharma Inc. (NASDAQ: REPH) is a pharmaceutical company that engages in the research and development of non-opioid therapeutics for the treatment of acute postoperative pain.

Its Acute Care segment focuses on developing innovative products for hospital and related settings. The Contract Development and Manufacturing segment leverages the company’s formulation expertise to develop and manufacture pharmaceutical products using the company’s proprietary delivery technologies for commercial partners who commercialize or plan to commercialize these products. Its products include Meloxicam, Dexmedetomidine and Fadolmidine.

Oppenheimer has an Outperform rating with a $15 price target. The posted consensus target is $8.70, and the shares closed trading at $8.51 on Friday.

TG Therapeutics

Takeover chatter on this company has been around for some time now. TG Therapeutics Inc. (NASDAQ: TGTX) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases.

Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. ublituximab (TG-1101) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics also is developing umbralisib (TGR-1202), an orally available PI3K delta inhibitor.

The Buy rating at Cantor Fitzgerald comes with a giant $17 price target, though the consensus target is slightly higher at $17.71. The stock most recently traded at $8.47 per share.

These are five more stocks for very aggressive accounts looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, these are not penny stocks with absolutely no track record or liquidity, and major Wall Street firms do have research coverage.